Fundraising Fox
Faeth Therapeutics
NASDAQ: FTHAustin, US · Delaware corporation · 42 employees on LinkedIn · 14 known investors
Find your way into Faeth Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Manan Shah to introduce you to Oliver Maddocks
You →Manan · together at University of Maryland School of Medicine →Oliver
Ask Jamie Chen to introduce you to Anand Parikh
You →Jamie · together at Virta Health →Anand
Sign up to find every way you can get introduced to Faeth Therapeutics
- Your email: who you already know at Faeth Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Faeth Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
Founders & leadership
Board
Investors · 14
How we know: the VCSheet dataset · Not right? Tell us
How we know: Cota Capital's portfolio page · Not right? Tell us
How we know: Future Ventures's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: S2G Investments's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.4M disclosed across 1 of 2 rounds · 1900–2025
▶$24.4MraisedJan 2026 · 35 investors · BiotechnologyRule 506(b)
- Jayson DallasDirector
- Anand ParikhExecutive Officer, Director, Promoter
- Alex MorganDirector
- Robert GouldDirector
- Stephen HahnDirector
- Oliver MaddocksExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $24.4M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Faeth Therapeutics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Faeth Therapeutics.
Frequently asked questions
- What does Faeth Therapeutics do?
- Faeth Therapeutics is a clinical-stage oncology company developing therapies that inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, PIKTOR, is an all-oral combination targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial and HR+/HER2- breast cancer.
- Who founded Faeth Therapeutics?
- Faeth Therapeutics was founded by Anand Parikh, Oliver Maddocks.
- Who are Faeth Therapeutics's investors?
- Faeth Therapeutics's investors include Able Partners, Atacama Ventures, Cota Capital, Future Ventures, iSelect Fund, S2G Investments, AgFunder, Baruch Future Ventures and 6 more.
- How much funding has Faeth Therapeutics raised?
- Faeth Therapeutics has disclosed $24.4M raised across 1 of its 2 known rounds.
- Where is Faeth Therapeutics headquartered?
- Faeth Therapeutics is headquartered in Austin, US.